Cholesterol Diagnosis Related to Breast Cancer Risk
By LabMedica International staff writers Posted on 22 Sep 2017 |

Image: Histopathology of breast cancer: intraductal carcinoma, comedo type, with distended duct with intact basement membrane and central tumor necrosis (Photo courtesy of Peter Abdelmessieh, DO, MSc).
Breast cancer is a malignancy that begins when cells grow abnormally in breast tissue. Although men can also develop breast cancer, it is much more common in women. Among women around the globe, breast cancer is the most common cancer and the fifth most common cause of cancer death. In 2012, nearly 1.7 million new cases, a quarter of all new cancer cases in women, were diagnosed worldwide.
All animal cells need cholesterol to function normally and it is an essential component of cell walls. Cholesterol is also important for making vitamin D, compounds that aid digestion, and hormones. The blood transports cholesterol around the body inside lipoproteins, which are droplets of fat covered with protein. However, having too much cholesterol in the blood is a well-established risk factor for cardiovascular conditions.
Scientists at Aston University (Birmingham, UK) collected information from over one million patients attending several hospitals in the North West of England between 2000 and 2013. They searched records from female participants aged 40 and over who were and were not diagnosed with high cholesterol at baseline (the start of the study period) and did not have breast cancer at that point. For their analysis, the team included 16,043 women who were diagnosed with high cholesterol and an age-matched group of the same number of women without high cholesterol for comparison. The average age of the women was 66 years.
The investigators found a lower proportion of the high-cholesterol group developed breast cancer, compared with the group that did not receive such a diagnosis at baseline (0.5% compared with 0.8%). Further analysis revealed significantly lower odds of breast cancer in the high-cholesterol patients (odds ratio of 0.67), compared with the patients who had not received such a diagnosis. The group that had been diagnosed with high cholesterol at baseline also had lower rates of death compared with the group that had not (13.8% compared with 23.7%). After taking into account age, ethnicity, and other factors known to influence premature death, the team found that the high-cholesterol group had significantly lower odds of death (odds ratio 0.60).
The team concluded that their large, longitudinal, retrospective study shows that diagnosis of high cholesterol has a highly protective effect on the subsequent development of breast cancer. Rahul Potluri, MD, a clinical scientist and the senior author of the study said, “If a diagnosis of high cholesterol leads to lower breast cancer rates this must either relate to something inherent in the condition or affected patients, or more likely, to treatment with widely used cholesterol lowering interventions such as statins.” The study was presented at the European Society of Cardiology ESC Congress, held August 26-30, 2017, in Barcelona, Spain.
Related Links:
Aston University
All animal cells need cholesterol to function normally and it is an essential component of cell walls. Cholesterol is also important for making vitamin D, compounds that aid digestion, and hormones. The blood transports cholesterol around the body inside lipoproteins, which are droplets of fat covered with protein. However, having too much cholesterol in the blood is a well-established risk factor for cardiovascular conditions.
Scientists at Aston University (Birmingham, UK) collected information from over one million patients attending several hospitals in the North West of England between 2000 and 2013. They searched records from female participants aged 40 and over who were and were not diagnosed with high cholesterol at baseline (the start of the study period) and did not have breast cancer at that point. For their analysis, the team included 16,043 women who were diagnosed with high cholesterol and an age-matched group of the same number of women without high cholesterol for comparison. The average age of the women was 66 years.
The investigators found a lower proportion of the high-cholesterol group developed breast cancer, compared with the group that did not receive such a diagnosis at baseline (0.5% compared with 0.8%). Further analysis revealed significantly lower odds of breast cancer in the high-cholesterol patients (odds ratio of 0.67), compared with the patients who had not received such a diagnosis. The group that had been diagnosed with high cholesterol at baseline also had lower rates of death compared with the group that had not (13.8% compared with 23.7%). After taking into account age, ethnicity, and other factors known to influence premature death, the team found that the high-cholesterol group had significantly lower odds of death (odds ratio 0.60).
The team concluded that their large, longitudinal, retrospective study shows that diagnosis of high cholesterol has a highly protective effect on the subsequent development of breast cancer. Rahul Potluri, MD, a clinical scientist and the senior author of the study said, “If a diagnosis of high cholesterol leads to lower breast cancer rates this must either relate to something inherent in the condition or affected patients, or more likely, to treatment with widely used cholesterol lowering interventions such as statins.” The study was presented at the European Society of Cardiology ESC Congress, held August 26-30, 2017, in Barcelona, Spain.
Related Links:
Aston University
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more